>
Switch to:

Morphic Holding Days Sales Outstanding

: 57.43 (As of Sep. 2021)
View and export this data going back to 2019. Start your Free Trial

Morphic Holding's average Accounts Receivable for the three months ended in Sep. 2021 was $1.97 Mil. Morphic Holding's Revenue for the three months ended in Sep. 2021 was $3.12 Mil. Hence, Morphic Holding's Days Sales Outstanding for the three months ended in Sep. 2021 was 57.43.

The historical rank and industry rank for Morphic Holding's Days Sales Outstanding or its related term are showing as below:

NAS:MORF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.78   Med: 59.16   Max: 74.54
Current: 70.75

43.78
74.54

During the past 4 years, Morphic Holding's highest Days Sales Outstanding was 74.54. The lowest was 43.78. And the median was 59.16.

NAS:MORF's Days Sales Outstanding is ranked lower than
54% of the 847 Companies
in the Biotechnology industry.

( Industry Median: 65.12 vs. NAS:MORF: 70.75 )

Morphic Holding's Days Sales Outstanding increased from Sep. 2020 (9.15) to Sep. 2021 (57.43).


Morphic Holding Days Sales Outstanding Historical Data

The historical data trend for Morphic Holding's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding Annual Data
Trend Dec17 Dec18 Dec19 Dec20
Days Sales Outstanding
- - 74.54 43.78

Morphic Holding Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Days Sales Outstanding Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.15 69.19 140.76 48.29 57.43

Competitive Comparison

For the Biotechnology subindustry, Morphic Holding's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Morphic Holding Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Morphic Holding's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Morphic Holding's Days Sales Outstanding falls into.



Morphic Holding Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Morphic Holding's Days Sales Outstanding for the fiscal year that ended in Dec. 2020 is calculated as

Days Sales Outstanding (A: Dec. 2020 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2019 ) + Accounts Receivable (A: Dec. 2020 )) / count ) / Revenue (A: Dec. 2020 )*Days in Period
=( (3.467 + 7.314) / 2 ) / 44.945*365
=5.3905 / 44.945*365
=43.78

Morphic Holding's Days Sales Outstanding for the quarter that ended in Sep. 2021 is calculated as:

Days Sales Outstanding (Q: Sep. 2021 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2021 ) + Accounts Receivable (A: Sep. 2021 )) / count ) / Revenue (A: Sep. 2021 )*Days in Period
=( (1.314 + 2.618) / 2 ) / 3.124*365 / 4
=1.966 / 3.124*365 / 4
=57.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Morphic Holding  (NAS:MORF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Morphic Holding Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Morphic Holding's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Morphic Holding Business Description

Morphic Holding logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
35 Gatehouse Drive, A2, Waltham, MA, USA, 02451
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
Executives
Farrell Robert E Jr officer: SVP Finance and CAO CAMBRIDGE DISCOVERY PARK 100 ACORN PARK DRIVE, 5TH FLOOR CAMBRIDGE MA 02140
Lugovskoy Alexey officer: Chief Development Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2 WALTHAM MA 02451
Devaul William officer: General Counsel and Secretary C/O MORPHIC HOLDING, INC. 35 GATEHOUSE DRIVE, A2 WALTHAM MA 02451
Slattery Joseph P director C/O TRANSENTERIX, INC. 635 DAVIS DRIVE, SUITE 300 MORRISVILLE NC 27560
Nashat Amir director 10835 ROAD TO THE CURE SUITE 205 SAN DIEGO CA 92121
Stampacchia Otello director 888 BOYLSTON ST., SUITE 1111 BOSTON MA 02199
Springer Timothy A director, 10 percent owner 36 WOODMAN ROAD CHESTNUT HILL MA 02467
Christensen Gustav director DYAX CORP. 300 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Bischofberger Norbert W director 333 LAKESIDE DR C/O GILEAD SCIENCES, INC. FOSTER CITY CA 94404
Goyal Vikas director C/O SR ONE, LTD., 161 WASHINGTON ST. SUITE 500, EIGHT TOWER BRIDGE CONSHOHOCKEN PA 19428
Rogers Bruce officer: Chief Scientific Officer C/O MORPHIC HOLDING, INC. 35 GATEHOUSE DRIVE, A2 WALTHAM MA 02451
Schegerin Marc officer: CFO and COO ARQULE INC 1 WALL ST FL6 BURLINGTON MA 01803
Linde Peter officer: Chief Medical Officer C/O MORPHIC HOLDING, INC. 35 GATEHOUSE DRIVE A2 WALTHAM ME 02451
Tipirneni Praveen P. director, officer: President and CEO C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2 WALTHAM MA 02451
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111 BOSTON MA 02199

Morphic Holding Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)